Faculty Opinions recommendation of Characterization of T-cell responses in macaques immunized with a single dose of HIV DNA vaccine.

Author(s):  
Willy Bogers ◽  
Petra Mooij
2009 ◽  
Vol 84 (3) ◽  
pp. 1243-1253 ◽  
Author(s):  
Géraldine Arrode-Brusés ◽  
Darlene Sheffer ◽  
Ramakrishna Hegde ◽  
Sukbir Dhillon ◽  
Zhengian Liu ◽  
...  

ABSTRACT The optimization of immune responses (IR) induced by HIV DNA vaccines in humans is one of the great challenges in the development of an effective vaccine against AIDS. Ideally, this vaccine should be delivered in a single dose to immunize humans. We recently demonstrated that the immunization of mice with a single dose of a DNA vaccine derived from pathogenic SHIVKU2 (Δ4SHIVKU2) induced long-lasting, potent, and polyfunctional HIV-specific CD8+ T-cell responses (G. Arrode, R. Hegde, A. Mani, Y. Jin, Y. Chebloune, and O. Narayan, J. Immunol. 178:2318-2327, 2007). In the present work, we expanded the characterization of the IR induced by this DNA immunization protocol to rhesus macaques. Animals immunized with a single high dose of Δ4SHIVKU2 DNA vaccine were monitored longitudinally for vaccine-induced IR using multiparametric flow cytometry-based assays. Interestingly, all five immunized macaques developed broad and polyfunctional HIV-specific T-cell IR that persisted for months, with an unusual reemergence in the blood following an initial decline but in the absence of antibody responses. The majority of vaccine-specific CD4+ and CD8+ T cells lacked gamma interferon production but showed high antigen-specific proliferation capacities. Proliferative CD8+ T cells expressed the lytic molecule granzyme B. No integrated viral vector could be detected in mononuclear cells from immunized animals, and this high dose of DNA did not induce any detectable autoimmune responses against DNA. Taken together, our comprehensive analysis demonstrated for the first time the capacity of a single high dose of HIV DNA vaccine alone to induce long-lasting and polyfunctional T-cell responses in the nonhuman primate model, bringing new insights for the design of future HIV vaccines.


Retrovirology ◽  
2009 ◽  
Vol 6 (Suppl 2) ◽  
pp. P21
Author(s):  
Géraldine Arrode-Brusés ◽  
Darlene Sheffer ◽  
Ramakrishna Hegde ◽  
Zhengian Liu ◽  
Francois Villenger ◽  
...  

2007 ◽  
Vol 178 (4) ◽  
pp. 2318-2327 ◽  
Author(s):  
Geraldine Arrode ◽  
Ramakrishna Hegde ◽  
Arunmani Mani ◽  
Yuhuai Jin ◽  
Yahia Chebloune ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Tor Kristian Andersen ◽  
Johanna Bodin ◽  
Fredrik Oftung ◽  
Bjarne Bogen ◽  
Siri Mjaaland ◽  
...  

The 2009 “swine flu” pandemic outbreak demonstrated the limiting capacity for egg-based vaccines with respect to global vaccine supply within a timely fashion. New vaccine platforms that efficiently can quench pandemic influenza emergences are urgently needed. Since 2009, there has been a profound development of new vaccine platform technologies with respect to prophylactic use in the population, including DNA vaccines. These vaccines are particularly well suited for global pandemic responses as the DNA format is temperature stable and the production process is cheap and rapid. Here, we show that by targeting influenza antigens directly to antigen presenting cells (APC), DNA vaccine efficacy equals that of conventional technologies. A single dose of naked DNA encoding hemagglutinin (HA) from influenza/A/California/2009 (H1N1), linked to a targeting moiety directing the vaccine to major histocompatibility complex class II (MHCII) molecules, raised similar humoral immune responses as the adjuvanted split virion vaccine Pandemrix, widely administered in the 2009 pandemic. Both vaccine formats rapidly induced serum antibodies that could protect mice already 8 days after a single immunization, in contrast to the slower kinetics of a seasonal trivalent inactivated influenza vaccine (TIV). Importantly, the DNA vaccine also elicited cytotoxic T-cell responses that reduced morbidity after vaccination, in contrast to very limited T-cell responses seen after immunization with Pandemrix and TIV. These data demonstrate that DNA vaccines has the potential as a single dose platform vaccine, with rapid protective effects without the need for adjuvant, and confirms the relevance of naked DNA vaccines as candidates for pandemic preparedness.


2017 ◽  
Vol 8 ◽  
Author(s):  
Juliana de Souza Apostólico ◽  
Victória Alves Santos Lunardelli ◽  
Marcio Massao Yamamoto ◽  
Higo Fernando Santos Souza ◽  
Edecio Cunha-Neto ◽  
...  

2000 ◽  
Vol 164 (8) ◽  
pp. 4393-4398 ◽  
Author(s):  
Barbara Bohle ◽  
Birgit Wagner ◽  
Ute Vollmann ◽  
Dietke Buck ◽  
Bodo Niggemann ◽  
...  

2021 ◽  
Author(s):  
Vivek Naranbhai ◽  
Wilfredo F Garcia-Beltran ◽  
Christhian Berrios Mairena ◽  
Julia Cara Thierauf ◽  
Christina Catherine Chang ◽  
...  

Background: Understanding variation in immunogenicity may help rationalize use of existing SARS-CoV-2 vaccines. Methods: We compared immune responses in ambulatory adults vaccinated with mRNA-1273 , BNT-162b2 or Ad26.COV2.S in Massachusetts, USA between February and May 2021. Control groups were pre-pandemic controls (n=1220) and individuals without (n=112) or with prior SARS-CoV-2 infection (n=130) sampled in mid-2020. We measured total anti-spike IgG/M/A antibodies (Roche Elecsys Anti-SARS-COV-2 S assay), anti-receptor-binding-domain (RBD) antibodies; neutralization of SARS-CoV-2 pseudovirus; and T-cell responses. Findings In individuals with prior infection, all vaccines were associated with higher antibody concentrations and neutralization than those in convalescent individuals, even after a single dose. In individuals without prior infection, a single dose of either mRNA vaccine yielded comparable concentrations and neutralization to convalescent unvaccinated individuals, and Ad26.COV2.S yielded lower antibody concentrations and neutralization titers. The second dose of either mRNA vaccine boosted responses. At a median of 24 days after vaccination, two of 21 (9.5%) Ad26.COV2.S recipients had a neutralization titer higher than pre-pandemic controls; repeat sampling at a median 66 days after vaccination found most (11/15 (73%) remained negative. Antibody concentrations and neutralization titers increased similarly after the first dose of either vaccine, and even further in recipients of a second dose of vaccine. T-cell responses were higher in mRNA1273 and BNT162b2 than Ad26.COV2.S recipients. Interpretation SARS-CoV-2 vaccines vary significantly in immunogenicity in individuals without prior infection. If confirmed in effectiveness studies, public health policy may need to be tailored to each vaccine, or even individual responses.


PLoS Medicine ◽  
2016 ◽  
Vol 13 (10) ◽  
pp. e1002139 ◽  
Author(s):  
John A. Todd ◽  
Marina Evangelou ◽  
Antony J. Cutler ◽  
Marcin L. Pekalski ◽  
Neil M. Walker ◽  
...  

PLoS ONE ◽  
2012 ◽  
Vol 7 (9) ◽  
pp. e45267 ◽  
Author(s):  
Rafael Ribeiro Almeida ◽  
Daniela Santoro Rosa ◽  
Susan Pereira Ribeiro ◽  
Vinicius Canato Santana ◽  
Esper Georges Kallás ◽  
...  

2010 ◽  
Vol 10 (6) ◽  
pp. 198 ◽  
Author(s):  
Su-Hyung Park ◽  
Mi-Young Song ◽  
Hyo Jung Nam ◽  
Se Jin Im ◽  
Young-Chul Sung

Sign in / Sign up

Export Citation Format

Share Document